West Pharmaceutical Services, Inc.
WST
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 23, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
68% downsideOvervalued by 68% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.81 Billion |
|---|---|
| Enterprise Value | $22.68 Billion |
| Dividend Yield | $0.87 (0.27%) |
| Earnings per Share | $6.83 |
| Beta | 1.17 |
| Outstanding Shares | 72,000,000 |
Return
| Return on Equity | 18.15% |
|---|---|
| Return on Assets | 13.21% |
| Return on Invested Capital | 19.12% |
Valuation & Multiples
| P/E Ratio | 42.83 |
|---|---|
| PEG | 78.49 |
| Price to Sales | 7.19 |
| Price to Book Ratio | 7.71 |
| Enterprise Value to Revenue | 7.04 |
| Enterprise Value to EBIT | 34.52 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.2919▲ 168.06% |
|---|---|
| Total Calls | 216,200▲ 52.79% |
| Total Puts | 495,500▲ 472.83% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 98.30%▲ 2.21% |
|---|---|
| Total Invested | $17.76B▼ 6.84% |
| Investors Holding | 764▼ 57.00% |
ESG Score
No data
About West Pharmaceutical Services, Inc.
CEO: Eric Green Relevant Senate Committees
This committee provides the technical analysis and revenue estimates for all tax legislation, directly influencing corporate tax structures and financial policies that impact West Pharmaceutical Services' profitability and investment decisions.
This committee controls taxation, trade, and entitlement spending (e.g., Medicare pricing). Its decisions directly impact WST's corporate profitability, international supply chains, and the revenue of its pharmaceutical customers through drug pricing policies.
This committee's subcommittees allocate discretionary federal spending, including for healthcare programs and scientific research, directly affecting the funding and market for WST's pharmaceutical customers and the broader healthcare industry.
This committee directly regulates the FDA and NIH, whose drug approval processes and research funding are paramount to the pharmaceutical and biotech sectors (WST's customers), directly influencing demand for WST's drug delivery components.